CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues:
Product sales, net	$ 379,880	$ 455,066	$ 341,750
Royalties	844	831	985
Total revenues	380,724	455,897	342,735
Costs and expenses:
Cost of sales (excluding amortization of intangible assets)	72,598	87,414	67,898
Research and development expenses	13,718	32,631	17,541
Acquired in-process research and development	24,900		54,900
Selling, general and administrative expenses	195,696	204,498	199,352
Amortization of intangible assets	102,745	106,845	83,344
Restructuring charges	13,247
Non-cash gain on settlement agreement			(29,900)
Total costs and expenses	422,904	431,388	393,135
(Loss) Income from operations	(42,180)	24,509	(50,400)
Other income (expense):
Gain on divestiture of Lazanda	17,064
Interest and other income	681	485	599
Loss on prepayment of Senior Notes	(5,938)	(5,777)
Interest expense	(73,552)	(83,719)	(73,436)
Total other expense	(61,745)	(89,011)	(72,837)
Net loss before income taxes	(103,925)	(64,502)	(123,237)
Benefit from (Provision for) income taxes	1,429	(24,218)	47,499
Net loss	$ (102,496)	$ (88,720)	$ (75,738)
Basic and diluted net loss per share (in dollars per share)	$ (1.63)	$ (1.45)	$ (1.26)
Shares used in computing basic and diluted net loss per share (in shares)	62,702,404	61,296,875	60,116,530